BRPI0720346A2 - Composições de depósito (depot) injetáveis e processo de preparação dessas composições. - Google Patents

Composições de depósito (depot) injetáveis e processo de preparação dessas composições.

Info

Publication number
BRPI0720346A2
BRPI0720346A2 BRPI0720346-2A2A BRPI0720346A BRPI0720346A2 BR PI0720346 A2 BRPI0720346 A2 BR PI0720346A2 BR PI0720346 A BRPI0720346 A BR PI0720346A BR PI0720346 A2 BRPI0720346 A2 BR PI0720346A2
Authority
BR
Brazil
Prior art keywords
compositions
preparing
injectable depot
depot compositions
injectable
Prior art date
Application number
BRPI0720346-2A2A
Other languages
English (en)
Inventor
Rajesh Jain
Kour Chand Jindal
Sampath Kumar Devarajan
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of BRPI0720346A2 publication Critical patent/BRPI0720346A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0720346-2A2A 2006-10-05 2007-10-03 Composições de depósito (depot) injetáveis e processo de preparação dessas composições. BRPI0720346A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2195DE2006 2006-10-05
PCT/IN2007/000473 WO2008041246A2 (en) 2006-10-05 2007-10-03 Injectable depot composition and its' process of preparation

Publications (1)

Publication Number Publication Date
BRPI0720346A2 true BRPI0720346A2 (pt) 2014-06-24

Family

ID=39268891

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0718288-0A2A BRPI0718288A2 (pt) 2006-10-05 2007-10-03 Composições de depósito injetável e processo de preparação de tais composições
BRPI0720346-2A2A BRPI0720346A2 (pt) 2006-10-05 2007-10-03 Composições de depósito (depot) injetáveis e processo de preparação dessas composições.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0718288-0A2A BRPI0718288A2 (pt) 2006-10-05 2007-10-03 Composições de depósito injetável e processo de preparação de tais composições

Country Status (17)

Country Link
US (2) US20100098735A1 (pt)
EP (2) EP2089000A2 (pt)
JP (2) JP2010505819A (pt)
KR (2) KR20090087441A (pt)
CN (2) CN101541313A (pt)
AR (1) AR063120A1 (pt)
AU (2) AU2007303793A1 (pt)
BR (2) BRPI0718288A2 (pt)
CA (2) CA2665101A1 (pt)
CL (1) CL2007002851A1 (pt)
EA (1) EA200970348A1 (pt)
IL (2) IL197947A0 (pt)
MA (2) MA30814B1 (pt)
MX (2) MX2009003735A (pt)
RU (1) RU2009116933A (pt)
TN (2) TN2009000124A1 (pt)
WO (2) WO2008041245A2 (pt)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
EP1589901A4 (en) * 2002-12-20 2006-08-09 Generipharm Inc INTRAKUTANE INJECTION
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US9205046B2 (en) * 2005-04-25 2015-12-08 The Governing Council Of The University Of Toronto Enhanced stability of inverse thermal gelling composite hydrogels
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
EP2152315B1 (en) 2007-05-25 2016-01-06 Indivior UK Limited Sustained delivery formulations of risperidone compounds
CN101677987A (zh) * 2007-06-22 2010-03-24 赛多斯有限责任公司 不含吐温80的多西他赛的增溶制剂
KR101892745B1 (ko) 2007-06-25 2018-08-28 오쓰까 세이야꾸 가부시키가이샤 코어/셀 구조를 가진 미소구
WO2009060473A2 (en) * 2007-11-06 2009-05-14 Panacea Biotec Limited Injectable compositions, processes and uses thereof
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
JP2011514349A (ja) 2008-03-07 2011-05-06 サイドース・エルエルシー フルベストラント配合物
US8524267B2 (en) * 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
CN101569622B (zh) * 2008-04-30 2012-11-21 天津药物研究院 一种用于注射给药的药物制剂及其制备方法
EA014044B1 (ru) * 2008-07-09 2010-08-30 Общество С Ограниченной Ответственностью "Аква-Альянс" Наносомальная лекарственная форма препарата пролонгированного действия для лечения гепатита с (варианты)
EP3685837A1 (en) * 2008-09-04 2020-07-29 Amylin Pharmaceuticals, LLC Sustained release formulations using non-aqueous carriers
US9498431B2 (en) 2008-12-10 2016-11-22 Jianjian Xu Controlled releasing composition
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
CA2754200A1 (en) * 2009-03-02 2010-09-10 Assistance Publique - Hopitaux De Paris Injectable biomaterial
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
JP5937004B2 (ja) 2009-05-18 2016-06-22 ドーズ メディカル コーポレーションＤｏｓｅ Ｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ 薬剤溶出眼内インプラント
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP3323423B1 (en) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
CN101669942A (zh) * 2009-09-29 2010-03-17 北京华禧联合科技发展有限公司 难溶性药物组合物
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
US9504698B2 (en) * 2009-10-29 2016-11-29 Warsaw Orthopedic, Inc. Flowable composition that sets to a substantially non-flowable state
JP5486690B2 (ja) 2009-11-16 2014-05-07 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ メラノコルチン受容体リガンドの医薬組成物
BR112012023303A2 (pt) * 2010-03-15 2020-08-25 Ipsen Pharma S.A.S. composição farmacêutica de ligantes do receptor do secretagogo do hormônio de crescimento.
JP2013523752A (ja) * 2010-03-29 2013-06-17 エボニック デグサ コーポレイション 局所投与部位における医薬組成物の保持改善のための組成物および方法
US10350159B2 (en) * 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
ES2390439B1 (es) 2012-08-03 2013-09-27 Laboratorios Farmacéuticos Rovi, S.A. Composición inyectable
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10335366B2 (en) * 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
DE102010023949A1 (de) * 2010-06-16 2011-12-22 F. Holzer Gmbh In-situ Lecithin-Mikroemulsionsgel-Formulierung
US20120046225A1 (en) 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
JP5575269B2 (ja) * 2010-08-24 2014-08-20 大塚製薬株式会社 カルボスチリル誘導体並びにシリコーンオイル及び／又はシリコーンオイル誘導体を含有する懸濁液及びケーキ組成物
CN103491961B (zh) * 2010-10-28 2018-01-02 艾库斯制药有限公司 阿立哌唑组合物和用于其经皮给药的方法
US9757374B2 (en) 2010-10-28 2017-09-12 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012122535A2 (en) 2011-03-10 2012-09-13 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
ES2972387T3 (es) * 2011-03-18 2024-06-12 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que comprenden ésteres de sorbitán
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
JP6117811B2 (ja) 2011-10-31 2017-04-19 ゼリス ファーマシューティカルズ インコーポレイテッド 糖尿病を処置するための製剤
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
EP2705835A1 (en) * 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
CN103483353B (zh) * 2012-06-13 2016-02-24 上海现代药物制剂工程研究中心有限公司 二硫杂环戊烯并吡咯酮化合物的纳米粒及制备方法
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
KR101811797B1 (ko) * 2013-04-03 2017-12-22 동국제약 주식회사 도네페질을 포함하는 비경구투여용 약제학적 조성물
WO2014179615A2 (en) * 2013-05-01 2014-11-06 Dae Won Park Biodegradable copolymers, systems including the copolymers, and methods of forming and using same
EP3063218A4 (en) * 2013-08-22 2017-07-26 Polyvalor, Limited Partnership Porous gels and methods for their preparation
JP2015093854A (ja) * 2013-11-12 2015-05-18 株式会社クレハ 水性組成物および加水分解抑制方法
CH708890B1 (de) * 2013-11-22 2018-03-15 Sandel Thomas Ball, vorzugsweise Golfball, sowie ein mit dem Ball kommunizierbares elektronisches Gerät.
US20150174254A1 (en) 2013-12-23 2015-06-25 Mcneil-Ppc, Inc. Topical gel compositions including polycaprolactone polymer and methods for enhancing the topical application of a benefit agent
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
AU2015266850B2 (en) 2014-05-29 2019-12-05 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
KR102428675B1 (ko) 2014-08-06 2022-08-02 엑스에리스 파머수티클스, 인크. 페이스트의 피내 및／또는 피하 주사를 위한 주사기, 키트, 및 방법
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MA40844A (fr) * 2014-11-10 2017-09-20 Glaxosmithkline Ip No 2 Ltd Compositions pharmaceutiques à action prolongée pour l'hépatite c
EP3028721A1 (en) * 2014-12-05 2016-06-08 Exchange Imaging Technologies GmbH Nanoparticle formulation having reverse-thermal gelation properties for injection
KR101692314B1 (ko) * 2015-03-27 2017-01-03 주식회사 주빅 지용성 약물의 생분해성 고분자 내 용해 시스템: 스마트 폴리머 시스템
US9844558B1 (en) 2015-04-30 2017-12-19 Amag Pharmaceuticals, Inc. Methods of reducing risk of preterm birth
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
US20170128424A1 (en) * 2015-11-11 2017-05-11 Qrono, Inc. Sustained release pharmaceutical compositions and methods of use
WO2017105512A1 (en) * 2015-12-18 2017-06-22 Proinvet Innovations S.A. Formulations and methods for controlling the reproductive cycle and ovulation
CA3022830A1 (en) 2016-04-20 2017-10-26 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
CA3022693A1 (en) * 2016-05-16 2017-11-23 Amag Pharmaceuticals, Inc. Polymeric extended release compositions of hydroxyprogesterone caproate and methods of using same
KR20240037175A (ko) 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018015915A1 (en) * 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
US20190380967A1 (en) * 2017-01-23 2019-12-19 Savior Lifetec Corporation Preparation of microparticles of an active ingredient
CN106822039A (zh) * 2017-01-24 2017-06-13 广州帝奇医药技术有限公司 水难溶或微溶性药物缓释组合物及其制备方法
CN106822043A (zh) * 2017-01-24 2017-06-13 广州帝奇医药技术有限公司 利培酮缓释组合物及其制备方法
CN106822042A (zh) * 2017-01-24 2017-06-13 广州帝奇医药技术有限公司 一种利培酮缓释组合物及其制备方法
CN106727422B (zh) * 2017-03-09 2018-10-02 王秋玉 一种聚对二氧环己酮为核的核-壳双层微球及其制备方法和应用
CN117085022A (zh) 2017-06-02 2023-11-21 Xeris药物公司 抗沉淀的小分子药物制剂
EP3681491A4 (en) 2017-09-11 2021-06-30 Atossa Therapeutics, Inc. PROCESS FOR MANUFACTURING AND USE OF ENDOXIFES
GB2568579B (en) * 2017-09-15 2022-06-29 Oxular Ltd Ophthalmic drug compositions
PT3562485T (pt) * 2018-03-23 2020-08-27 Laboratoires Major Composições e métodos não hormonais para contraceção masculina compreendendo (r)-silodosina
PE20210047A1 (es) 2018-06-12 2021-01-08 Farm Rovi Lab Sa Composicion inyectable
BR112021007900A2 (pt) * 2018-08-10 2021-08-03 Ephemeral Solutions, Inc. partículas contendo agentes de coloração e métodos de uso das mesmas
US11896715B2 (en) 2019-06-21 2024-02-13 Korea University Research And Business Foundation In vivo bulking agent, injection comprising same, and preparation method therefor
WO2021003433A1 (en) 2019-07-03 2021-01-07 Atossa Therapeutics, Inc. Sustained release compositions of endoxifen
CN111388744B (zh) * 2020-01-15 2021-05-18 华中科技大学 一种凝胶贮库及其制法与制备术后止血制剂的应用
CN116669717A (zh) * 2020-08-17 2023-08-29 美国人福制药公司 长效原位成型/胶凝组合物
CN111956599B (zh) * 2020-09-29 2023-02-17 江苏集萃新型药物制剂技术研究所有限公司 皮下植入药剂及其组合物和制备方法
KR102266384B1 (ko) * 2021-01-25 2021-06-21 주식회사 울트라브이 필러용 생분해성 고분자 미세입자, 이를 포함한 필러용 동결건조체, 그 제조방법 및 상기 동결건조체를 포함하는 필러용 주사제
US12318387B2 (en) 2021-07-16 2025-06-03 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
US12594236B2 (en) 2021-07-16 2026-04-07 Laboratorios Farmaceuticos Rovi, S.A. Method of treating acute exacerbation of schizophrenia with long-acting injectable depot composition
KR102652905B1 (ko) * 2021-08-09 2024-04-01 주식회사 메디폴리머 주사용 사전-제형 및 이를 이용한 도네페질 초기방출 억제형 키트
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物
WO2023233051A1 (es) 2022-05-18 2023-12-07 Laboratorios Farmacéuticos Rovi, S.A. Composiciones inyectables de liberación prolongada para su uso en el tratamiento con risperidona junto a inhibidores de la enzima cyp2d6
WO2024151625A1 (en) * 2023-01-10 2024-07-18 Georgetown University Non-toxic plga compositions and methods of making and using same
CN116850146B (zh) * 2023-05-22 2024-05-14 济南大学 伏硫西汀自由碱或其药用盐长效缓释制剂及其制备方法
WO2025153747A1 (es) 2024-01-17 2025-07-24 Laboratorios Farmacéuticos Rovi, S.A. Composiciones y esquemas de dosificación de inhibidores de aromatasa mejorados
USD1137672S1 (en) 2024-08-27 2026-07-28 Glaukos Corporation Drug eluting ocular implant

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242910A (en) * 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
EP0669128B1 (en) * 1992-11-17 2000-01-05 Yoshitomi Pharmaceutical Industries, Ltd. Sustained-release microsphere containing antipsychotic and process for producing the same
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
GB9718986D0 (en) * 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
WO2002058672A2 (en) * 2001-01-26 2002-08-01 Debio Recherche Pharmaceutique S.A. Microparticles of biodegradable polymer encapsulating a biologically active substance
ES2541908T3 (es) * 2001-10-10 2015-07-28 Pierre Fabre Medicament Microesferas biodegradables de liberación prolongada y su procedimiento de preparación
TW200719903A (en) * 2005-04-19 2007-06-01 Combinatorx Inc Compositions for the treatment of neoplasms

Also Published As

Publication number Publication date
WO2008041245A2 (en) 2008-04-10
IL197947A0 (en) 2009-12-24
CA2665105A1 (en) 2008-04-10
MA30814B1 (fr) 2009-10-01
AU2007303793A1 (en) 2008-04-10
RU2009116933A (ru) 2010-11-10
KR20090087441A (ko) 2009-08-17
EA200970348A1 (ru) 2009-10-30
MX2009003737A (es) 2009-06-16
WO2008041246A2 (en) 2008-04-10
KR20090094811A (ko) 2009-09-08
WO2008041245A3 (en) 2008-05-22
BRPI0718288A2 (pt) 2013-11-19
CN101541313A (zh) 2009-09-23
JP2010505821A (ja) 2010-02-25
WO2008041246A3 (en) 2008-05-29
IL197946A0 (en) 2009-12-24
JP2010505819A (ja) 2010-02-25
CN101541316A (zh) 2009-09-23
US20100015195A1 (en) 2010-01-21
CA2665101A1 (en) 2008-04-10
TN2009000125A1 (en) 2010-10-18
MA30817B1 (fr) 2009-10-01
TN2009000124A1 (en) 2010-10-18
US20100098735A1 (en) 2010-04-22
MX2009003735A (es) 2009-04-22
EP2086505A2 (en) 2009-08-12
AU2007303794A1 (en) 2008-04-10
CL2007002851A1 (es) 2008-01-18
EP2089000A2 (en) 2009-08-19
AR063120A1 (es) 2008-12-30

Similar Documents

Publication Publication Date Title
IL197946A0 (en) Injectable depot compositions and process for producing the same
BRPI0820139A2 (pt) Composição antiperspirante ativa, e, processo de obtenção de uma composição antiperspirante ativa
BRPI0815841A2 (pt) Métodos e composições para melhoramento de traços preferidos.
BRPI0911767A2 (pt) Processo, e, composto.
BRPI0906249A2 (pt) Processo de elaboração de 1,1,1,4,4,4-hexafluoro-2-buteno
SMP200900058B (it) Composti e composizioni come inibitori di proteinachinasi.
SM201000108A (it) Composti e composizioni come inibitori di proteinachinasi.
BRPI0919624A2 (pt) processo de descontaminação de gás de síntese.
EP2067800A4 (en) POLYORGANOSILOXANE COMPOSITION
BRPI0720312A2 (pt) Composição de engomagem, fibra de vidro, composição combinada e método para produzir um composto reforçado com fibra de vidro.
EP4125244C0 (en) HASH BASED MULTIHOSTING
BRPI0812054A2 (pt) Processo para preparar compostos, e, compostos.
BRPI1011423A2 (pt) composição injetável, kit e método cosmético.
BRPI0809573A8 (pt) composição, e, método
BRPI0716046A2 (pt) composiÇÕes de nanopartÍcula.
BRPI0718075A2 (pt) Processo de hidrogenação
BRPI0718386A2 (pt) Processo para preparação de catalisadores.
BRPI0914221A2 (pt) processo, e, composto
BRPI0719272A2 (pt) Composição de enzima, e, método para preparar uma composição de enzima.
BRPI0815922A2 (pt) Artigo, composição, e, método.
BRPI0814167A2 (pt) Composição, e, método
BRPI0720530A2 (pt) Partícula, processo para preparar a partícular, e, composição
BRPI0718999A2 (pt) Pirazois substituídos, composições que os contêm, processo de produção e utilização
BRPI0914924A2 (pt) processo para preparar aminobifenilas, e, composto.
BRPI0718324A2 (pt) Métodos para o tratamento de depressão.

Legal Events

Date Code Title Description
B08L Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 4A, 5A, 6A E 7A ANUIDADES.

B08I Publication cancelled [chapter 8.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2277 DE 26/08/2014 POR TER SIDO INDEVIDA.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A, 7A, 8A, 9A, 10A, 11A, 12A E 13A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.